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Summary
Primary familial and congenital polycythaemia (PFCP) is a disease character-
ized by increased red blood cell mass, and can be associated with mutations
in the intracellular region of the erythropoietin (EPO) receptor (EPOR). Here
we explore the mechanisms by which EPOR mutations induce PFCP, using
an experimental system based on chimeric receptors between epidermal
growth factor receptor (EGFR) and EPOR. The design of the chimeras
enabled EPOR signalling to be triggered by EGF binding. Using this system
we analysed three novel EPOR mutations discovered in PFCP patients: a dele-
tion mutation (Del1377-1411), a nonsense mutation (C1370A) and a mis-
sense mutation (G1445A). Three different chimeras, bearing these mutations
in the cytosolic, EPOR region were generated; Hence, the differences in the
chimera-related effects are specifically attributed to the mutations. The results
show that the different mutations affect various aspects related to the signal-
ling and metabolism of the chimeric receptors. These include slower degrada-
tion rate, higher levels of glycan-mature chimeric receptors, increased
sensitivity to low levels of EGF (replacing EPO in this system) and extended
signalling cascades. This study provides a novel experimental system to study
polycythaemia-inducing mutations in the EPOR, and sheds new light on
underlying mechanisms of EPOR over-activation in PFCP patients.
Keywords: myeloproliferative disorder, erythrocytosis, erythropoietin recep-
tor, chimeric receptors.
Absolute erythrocytoses are rare disorders characterized by a
significant increase of the red blood cell mass, which is
reflected by an increased number of circulating erythrocytes,
high haematocrit and haemoglobin (Lorberboym et al, 2005;
Cario et al, 2013). Primary familial and congenital polycy-
thaemia [PFCP, familial erythrocytosis type 1, Online
Mendelian Inheritance in Man (OMIM) number 133100] is
an inherited form of this disease, caused by erythropoietin
(EPO) hypersensitivity of erythroid precursor cells (Sokol
et al, 1995; Kralovics & Prchal, 2001; Maran & Prchal, 2004;
Perrotta et al, 2010). Patients with PFCP have relatively
low serum levels of EPO (Rives et al, 2007), normal leuco-
cyte and platelet counts, hypersensitivity of erythroid pro-
genitors to EPO and normal oxygen affinity to haemoglobin
(Jedlickova et al, 2003; Maran & Prchal, 2004). The clinical
symptoms of PFCP include headaches, muscle aches, dizzi-
ness, epistaxis and an increased risk of thrombotic and
haemorrhagic events leading to premature morbidity (Percy
et al, 1998; Al-Sheikh et al, 2008; Perrotta et al, 2010). The
common treatment for PFCP is phlebotomy (Perrotta et al,
2010).
A number of mutations in the cytosolic region of the EPO
receptor (EPOR) have been found in family members suffer-
ing from PFCP (de la Chapelle et al, 1993). EPO is the major
cytokine that induces erythropoiesis via growth, differentia-
tion and maturation of erythroid progenitors (Budarf et al,
1990; Casadevall et al, 2002; Perrotta et al, 2010). EPO is
produced mainly in the kidney under hypoxic conditions. It
acts on erythroid progenitors in the adult bone marrow after
binding to EPOR, a homodimeric transmembrane receptor.
EPOR belongs to the superfamily of cytokine receptors
(Bazan, 1989; Halaby & Mornon, 1998; Constantinescu et al,
1999; Watowich, 2011) and the mature protein is 508
amino-acids long (Smith et al, 2003; Perrotta et al, 2010).
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EPOR lacks kinase activity, hence the signalling cascade is
initiated through its association with Janus kinase 2 (JAK2).
EPO binding to the extracellular domain of EPOR induces
dimerization of the receptor and transphosphorylation of the
associated JAK2 on both receptor monomers (Argetsinger
et al, 1993; Hortner et al, 2002). JAK2 then phosphorylates
tyrosine residues on EPOR which serve as docking sites for a
variety of molecules, some of which participate in promoting
signalling cascades and others serve as negative regulatory
mediators (Argetsinger et al, 1993).
Most of the PFCP-inducing mutations in EPOR result in
a C-terminal truncated receptor that lacks the negative regu-
latory domain (Kralovics & Prchal, 2001; O’Rourke et al,
2011). However, so far, no missense mutations have been
identified as the cause of PFCP, despite of the fact that they
are found in PFCP patients (Kralovics & Prchal, 2001;
Gordeuk et al, 2005; Percy & Lee, 2008).
Our strategy was to explore the signalling and metabolism
of such mutated EPORs in an in vitro system that is based
on chimeric receptors which are constructed from the intra-
cellular region of EPOR and the extracellular and transmem-
brane regions of the epidermal growth factor receptor
(EGFR), a tyrosine kinase also known as HER1 or ErbB-1
(Yarden, 2001; Krampera et al, 2005; Normanno et al, 2006).
Chimeric receptors containing EPOR or EGFR (Zou et al,
2008; Kuhns et al, 2010; Tachdjian et al, 2010; Cummings
et al, 2013), as well as EGFR-EPOR chimeras (Yu et al, 2002;
Buchse et al, 2006), were previously used as experimental
tools to study specific receptor domains. Accordingly, EGF
binding to the extracellular domain of the chimera triggers
the EPOR signalling cascades. The working hypothesis was
that the EPOR cytosolic region of the EGFR-EPOR chimera,
when corresponding to mutations found in PFCP patients,
would confer properties to the chimera that could explain
the observed PFCP-associated manifestations. The con-
structed chimeras were transfected into the EPO-dependent
UT7 erythroid cell line, which does not express EGFR and
does not respond to EGF (data not shown). Thus, the differ-
ences in signalling and metabolism of the chimeric EGFR-
EPORs, generated on the basis of the PFCF-associated EPOR
mutations, could be discerned. The extracellular EFGR
domain of the chimeras was HA-tagged, to facilitate immu-
nological detection.
Here we report on using this experimental system to
explore three novel EPOR mutations, found in PFCP
patients, which were not previously explored (Fig 1):
1 C1370A: a nonsense mutation (c.1235C>A; p.(Ser412*)),
found in a 73-year-old male with erythrocytosis
(unknown if hereditary or not, because other family
members were not reported) (Bento et al, 2013). The
mutation results in the transformation of TCG to TAG,
generating a stop codon, which leads to the truncation of
97 C-terminal amino acids of EPOR.
2 Del1377-1411: deletion of 35 nucleotides (c.1242_1276del;
p.(Ser415Hisfs*18)). The mutation results in a frameshift,
alteration of 18 amino acids and truncation of 65 C-ter-
minal amino acids. This mutation has not previously been
reported.
3 G1445A: a missense mutation (c.1310G>A; p.(Arg437His)),
discovered in two families with PFCP, one of them suffer-
ing also from Hereditary Spherocytosis (HS), a type of hae-
molytic anaemia characterized by sphere-shaped
erythrocytes. This substitution results in the replacement of
arginine 437 by histidine and has no effect on the size of
EPOR. This mutation has not previously been reported.
Materials and methods
Cell culture
UT7 cells were cultured in Iscove’s Modified Dulbecco’s
Medium (IMDM) containing 10% fetal calf serum (FCS),
2 mmol/l L-glutamine, 10 u/ml penicillin, 10 lg/ml strepto-
mycin and 10 ng/ml EGF (Biotest, Solihull, UK) at 37°C and
5% CO2.
Construction of the wild type (WT) EGFR-EPOR
chimera
Human EGFR-HA in pcDNA3 was a gift from Prof. R. Pinkas-
Kramarski (Tel Aviv University, Israel). Human EPOR was
kindly provided by Prof. Y. Henis (Tel Aviv University, Israel)
and cloned into pcDNA3. Primers: Extracellular region (50
end) of EGFR – sense 50ATGCGACCCTCCGGGACGGC 30;
Transmembrane region (30 end) of EGFR and Intracellular
region (50 end) of EPOR – anti-sense 50 CCCGGCGGTGC
ATGAAGAGGCCGATC 30. Intracellular region (30 end) of
EPOR – sense 50CTAAGAGCAAGCCACATAGC 30 Intracellu-
lar region (50 end) of EPOR and transmembrane region (30
end) of EGFR – anti-sense 50 CCTCTTCATGCACCGCCGG
GCTCTGA 30.
Fig 1. Schematic illustration of the wildtype (WT) and mutated
EGFR-EPOR chimeras. Diagonal stripes: HA tag. White boxes:
EGFR. Large white boxes in EGFR extracellular region: cysteine-rich
sites. Black boxes: EGFR transmembrane region. Grey: WT EPOR
intracellular domain. Light grey: amino acid alteration. Black hori-
zontal line in G1445A: location of amino acid substitution. WT,
wildtype; EGFR, epidermal growth factor receptor; EPOR, erythro-
poietin receptor.
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Mutagenesis
Mutagenesis of the WT EGFR-EPOR chimera was performed
using QuikChange Site-Directed Mutagenesis kit (Bio-Lab,
Jerusalem, Israel). All primers were ordered from HyLabs
(Rehovot, Israel).
UT7 transfection
UT7 cells were transfected using electroporation, as described
(Ghaffari et al, 2003). The electroporation mixture contained
20 mmol/l PIPES, 128 mmol/l Glutamate, 10 lmol/l Ca-ace-
tate, 2 mmol/l Mg-acetate and 3:4 IMDM medium. Electropo-
ration parameters were 300 mV, 20 ms. The electroporation
device was an ECM 830 (BTX HARVARD APPARATUS, Holl-
iston, MA, USA). Selection of the transfected clones was per-
formed in the presence of 10 ng/ml EGF for at least 3 weeks.
EPOR signalling
Transfected UT7 cells were grown for 24 h in IMDM, in the
absence of serum and growth factor (EGF or EPO). Cells
were then collected and activated with 100 ng/ml EGF and
lysed in lysis buffer containing 50 mmol/l Tris/HCl, 1% Tri-
ton, 150 mmol/l NaCl, 5 mmol/l EDTA and freshly-added
Protease Inhibitor Cocktail (PIC; Roche Diagnostics, Basel,
Switzerland).
Degradation assay
Transfected UT7 cells were incubated for different time inter-
vals in IMDM in the absence of EGF and EPO, in the pres-
ence of 035 mmol/l cycloheximide (Sigma, St. Louis, MO,
USA). Cells were then lysed, using the above-mentioned cell
lysis buffer.
Antibodies
For Western blot analysis: anti-HA (MMS-101R; Covance,
Princeton, NJ, USA), actin (MAB1501; Millipore, Billerica,
MA, USA), pSTAT5 (9351; Cell Signaling, Danvers, MA,
USA), pMAPK (4377; Cell Signaling) (which detects only
pERK1/2), STAT5 (sc-836; Santa Cruz Biotechnology, Dallas,
TX, USA), ERK (sc-154; Santa Cruz Biotechnology) were
used. Anti-HA (MMS-101R; Covance) and fluorescein isothi-
ocyanate (FITC)-conjugated Affinipure Goat anti-Mouse IgG
(115-095-003; Jackson Immunoresearch, West Grove, PA,
USA) were used for fluorescence-activated cell sorting
(FACS) analysis.
Western blot analysis
Samples were loaded onto 75% polyacrylamide gels and sep-
arated via electrophoresis. Gels were transferred onto nitro-
cellulose membrane filters and probed with the relevant
antibodies. The enhanced chemiluminescence (ECL) method
was used for detection (Pollard-Knight et al, 1990).
Flow cytometry
Transfected UT7 cells were washed in cold phosphate-
buffered saline and incubated for 1 h with 1:100 anti-HA
antibody. Cells were washed again and incubated for 1 h
with 1:100 FITC-labelled anti-mouse antibodies. Fluorescence
detection was performed by FACSort flow cytometer [Becton
Dickinson (BD), Franklin Lakes, NJ, USA] and results
were analysed using WINMDI 2.8 Software (J.Trotter; free
download).
Glycan-maturation
Cells were lysed in the whole-cell lysis buffer and incubated
for 1 h with 500 units Endoglycosidase H (Endo H, p0703L;
Bio-labs) at 37°C.
Cell viability
Transfected UT7 cells were seeded in triplicates in 96-well,
flat-bottom culture plates (5 9 103 cells per well) and incu-
bated at 37°C with EGF (at the indicated concentrations) for
0, 24, 48 and 72 h. Cell viability was determined using the
colourimetric methyl-thiazole-tetrazolium bromide (MTT)
(Sigma) assay (Gerlier & Thomasset, 1986). After incubation,
5 lg/ml MTT was added to the cells and they were further
incubated at 37°C for 3 h. The dye was completely solubi-
lized with 004 N HCl in 2-propanol and plates were read at
570 nm in an enzyme-linked immunosorbent assay (ELISA)
reader (SpectraMAX 190; Molecular Devices, Sunnyvale, CA,
USA).
Results
Viability and growth patterns of cells expressing the
EPOR mutations
To address whether the EPOR cytosolic mutations affect the
sensitivity of UT7 cells, expressing the WT and chimeric
receptors, to EGF, we performed the MTT cell viability assay
(Fig 2). UT7 cells expressing chimeric receptors with EPOR
portions derived from the PFCP patients exhibited different
growth patterns than cells expressing the chimera containing
the WT EPOR cytosolic domain (Fig 2). Cells expressing the
mutated chimeric receptors were more viable, proliferated
faster, and were responsive even to very low (001 ng/ml)
EGF concentrations. In contrast, cells expressing the WT
EGFR-EPOR chimera did not proliferate at all in the lowest
EGF concentration, 001 ng/ml, while all other three cell
lines, expressing the chimeras containing EPOR mutations
from the PFCP patients, exhibited different growth patterns
(Fig 2A). At 01 ng/ml EGF (Fig 2B) all three chimeras of
PFCP-Related EPOR Mutations Studied by EGFR-EPOR Chimeras
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the EPOR PFCP mutants conferred significantly increased
EGF-dependent growth, compared to WT, at all times. At
1 ng/ml EGF (Fig 2C), no difference in growth between WT
and C1370A expressing cells was observed. Cells expressing
the Del1377-1411 or G1445A chimeras showed higher levels
of proliferation for all time periods tested. The proliferation
rates of C1370A expressing cells at 10 ng/ml EGF (Fig 2D)
were similar to those of cells expressing the WT chimera,
while Del1377-1411 expressing UT7 cells proliferated at a
higher rate for 24 and 48 h. However this difference disap-
peared after 72 h. Once again, G1445A expressing cells
showed higher levels of proliferation at all times. The ability
of the EGFR-EPOR chimeras to confer EGF-mediated prolif-
eration was reflected in enhanced EGF-mediated proliferative
responses of the chimeras, indicating the reliability of this
experimental system. Notably, all mutated EGFR-EPOR
chimeras conferred proliferation of UT7 cells even when cul-
tured in the absence of growth factor (data not shown).
All three EPOR mutations increased the sensitivity of the
cells to EGF, yet variations in the amplitude of responses
between the chimeras were detected – thus pointing out dis-
tinct EGF-mediated growth capacity of the WT and mutated
chimeras. Consequently, all EPOR mutations hereby tested
can be linked to higher proliferation rates of the cells, includ-
ing the missense EPOR mutation (G1445A) which, to date,
has not been linked to a polycythaemic phenotype.
Cell surface expression and glycan maturation of the
EGFR-EPOR chimeras
Given that differences in the growth patterns of cells express-
ing the WT and mutated chimeric receptors have been
observed, a panel of experiments was initiated in order to
detect the possible mechanisms which attribute to the
enhanced proliferation of cells expressing the EGFR-EPOR
chimeras that harbour PFCP-associated EPOR mutations.
These possible mechanisms include modulation of cell sur-
face levels of the chimeras, changes in their metabolism (e.g.
degradation, glycan maturation) and altered EGF-driven sig-
nalling cascades.
To measure the cell surface level of the chimeras under vari-
ous EGF concentrations, flow cytometry analysis was per-
formed (Fig 3). The results showed the following: (i) The cell
surface levels of the WT EGFR-EPOR chimera following cul-
ture of the cells in 001 ng/ml EGF were significantly lower,
compared to those on the surface of cells cultured in 10 ng/ml
(A) (B)
(C) (D)
Fig 2. Viability of UT7 cells expressing EGFR-EPOR chimeras. UT7 cells, expressing WT or mutated EGFR-EPORs, were incubated for 0, 24, 48
and 72 h with the indicated concentrations 001 ng/ml (A), 01 ng/ml (B), 1 ng/ml (C) and 10 ng/ml (D) of EGF. Cell viability was determined
using the MTT method. OD570 nm at time 0 for each mutant was considered 100%. Proliferation of UT7 cells expressing each EGFR-EPOR chi-
mera was calculated with respect to the corresponding 100% (time 0). Bars indicate mean  standard deviation, N = 4, each experiment was per-
formed in triplicates. **P < 005 compared to WT levels at 24 h, ##P < 005 compared to WT levels at 48 h, ^^P < 005 compared to WT levels
at 72 h. WT, wildtype; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; EPOR, erythropoietin receptor; MTT, methyl-
thiazole-tetrazolium bromide; OD, optical density.
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EGF (Fig 3). (ii) The cell surface levels of EGFR-EPOR
C1370A were higher when the cells were incubated in
001 ng/ml EGF as compared to their levels at 10 ng/ml
EGF. At both high and low EGF concentrations, the cell sur-
face levels of this EGFR-EPOR chimera were higher than
those of the WT EGFR-EPOR. (iii) Lower levels of cell sur-
face EGFR-EPOR Del1377-1411 compared to those of WT
EGFR-EPOR were measured when the respective cells were
grown in 10 ng/ml EGF. However, in 001 ng/ml EGF, the
surface levels of EGFR-EPOR Del1377-1411 were elevated
and approached those of the WT EGFR-EPOR chimera. (iv)
G1445A expressing cells presented increased cell surface lev-
els of the chimera at 001 ng/ml EGF, compared to the levels
detected at 10 ng/ml EGF. Yet, at both EGF concentrations,
the levels of G1445A were significantly lower than those of
the WT EGFR-EPOR.
A possible explanation for the differences in cell surface
levels of EGFR-EPOR in high and low EGF concentrations
may be derived from a different pool of mature and imma-
ture chimeras in cells expressing the WT and mutated recep-
tors. EndoH removes high mannose residues, which are a
characteristic ER modification, thereby enabling the detection
of ER-and-Golgi glycan immature and mature forms
(Fig 4A). Lysates of the cells expressing the chimeras were
subjected to EndoH digestion and Western blot analysis, and
probed with anti-HA antibodies. Quantification of Western
blots revealed that C1370A and Del1377-1411 have signifi-
cantly higher levels of glycan mature chimeras and lower lev-
els of glycan immature chimeras compared to the WT
EGFR-EPOR, and G1445A is significantly less glycan-mature,
as shown by the higher levels of immature chimera compared
to WT EGFR-EPOR (Fig 4B).
Degradation of the EGFR-EPOR chimeras
To further elucidate the metabolism of the WT and mutated
chimeric receptors, we measured the degradation rates of the
chimeric receptors after inhibiting protein synthesis with
cycloheximide for 0–5 h. The results showed the following:
(i) Two chimeric receptors, C1370A and Del1377-1411
exhibited significantly slower degradation rates after 1, 2, 3
and 5 h or 2, 3 and 5 h respectively, compared to the WT
chimera (Fig 5). (ii) G1445A did not exhibit any significant
difference in degradation rates compared to WT EGFR-
EPOR. A difference in the degradation patterns was also
observed: (i) The WT and G1445A chimeras showed consis-
tent degradation over the first 5 h with cycloheximide. (ii)
C1370A and Del1377-1411 exhibited a considerably slower
decline in the receptor levels.
Intracellular signalling mediated by the EGFR-EPOR
chimeras
Another possible explanation for the enhanced proliferation
of cells expressing the mutated chimeras might be attributed
to extended signalling cascades triggered by the mutated
forms of EPOR. Therefore, the kinetics of two signalling cas-
cades, STAT5 and MAPK/ERK, activated upon EPO binding
to EPOR, were explored. (i) STAT5 signalling was similar
Fig 3. Levels of WT and mutated chimeric receptors on the cell sur-
face. Cell surface levels of WT and mutated EGFR-EPOR were mea-
sured by flow cytometry analysis. Cells were grown on media
containing 001 ng/ml or 10 ng/ml EGF for 24 h. Results were nor-
malized to cell surface levels of WT chimera expressing cells grown
in 10 ng/ml EGF. Bars indicate mean  standard error of the mean,
N ≥ 3. **P < 005 compared to WT chimera with 10 ng/ml
EGF, ##P < 005 compared to WT chimera with 001 ng/ml EGF,
^^P < 005 comparison between surface levels of the chimeras at
10 ng/ml and 001 ng/ml EGF. WT, wildtype; EGF, epidermal
growth factor; EGFR, epidermal growth factor receptor; EPOR,
erythropoietin receptor.
(A)
(B)
Fig 4. Glycan maturation of EGFR-EPOR chimeras. Sensitivity of
the chimeric receptors to digestion by EndoH indicates their glycan
maturation at steady state. (A) Representative Western blots of pro-
tein extracts from cells expressing WT, and mutated EGFR-EPOR
chimeras. (B) Mean value of the quantifications of the Western Blots.
Percentages of mature (upper band) and immature (lower band)
forms of the chimeras were calculated with respect to the total
amount of protein (the sum of mature and immature forms). Bars
indicate mean  standard deviation, N = 3. **P < 005 compared to
the percentage of glycan-immature WT chimera. ##P < 005 com-
pared to the percentage of glycan-mature WT chimera. WT, wild-
type; EGFR, epidermal growth factor receptor; EPOR, erythropoietin
receptor; Endo H, Endoglycosidase H.
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in cells expressing the WT and Del1377-1411 chimeras
(Fig 6A–B). (ii) The basal level of phosphorylated-STAT5
(pSTAT5) in cells expressing C1370A was far higher than in
cells expressing all other chimeric receptors, and higher levels
of pSTAT5 were observed in cells expressing the C1370A
chimera compared to cells expressing the WT chimera after
30–60 min. These results may be attributed to constitutive
activation of the mutated chimeric receptor (Fig 6A–B), and
correspond to our observation that cells expressing this
mutated receptor show ligand-independent growth. (iii) This
signalling cascade was delayed in cells expressing the G1445A
chimera, but the activation and attenuation patterns were
similar to the WT.
The ERK1/2 signalling cascade proved to be similar in
WT, C1370A and Del1377-1411 expressing cells (Fig 6C–D),
whereas the activation of this signalling cascade appeared to
be delayed in cells expressing G1445A. However, higher lev-
els of pERK persisted after 60 min in cells expressing
G1445A than those in cells expressing the WT chimeric
receptor. This result thus suggests also slower attenuation of
this signalling cascade mediated by the G1445A substitution
(Fig 6C–D).
Discussion
PFCP is characterized by the enhanced production of ery-
throcytes (Rives et al, 2007), and some PFCP cases have been
attributed to mutations in the cytosolic region of the EPOR.
The vast majority of these mutations result in a truncated
receptor and the loss of its negative regulatory domain.(Kra-
lovics & Prchal, 2001; O’Rourke et al, 2011).
Currently, the methods used to assess the mechanisms by
which these EPOR mutations induce polycythaemia have
been based on cells retrieved from PFCP patients or from
polycythaemic mice (Maran & Prchal, 2004; Perrotta et al,
2010). As these cells do not readily grow and proliferate in
culture, exploring EPO-driven signalling cascades in them is
limited, and information derived from these methods is defi-
cient. Furthermore, EPOR in mice and humans, though lar-
gely homologous, differ slightly in the amino acid sequence,
hence mutations in a certain region in one receptor are not
necessarily parallel to the same mutations in the other (Burns
et al, 2002). Moreover, most of the studies regarding EPOR
mutations have been performed on murine EPOR and/or on
murine cell lines. In addition to the aforementioned differ-
ences between human and murine EPORs, some of these cell
lines do not endogenously express EPOR and thus do not
respond naturally to EPO.
Here we report on the generation of an experimental sys-
tem based on chimeric human EGF-EPO receptors. The
EPOR portion of these chimeras was derived from mutations
found in EPORs of PFCP patients. The resulting chimeras
were stably transfected into the EPO-dependent human ery-
throleukaemia UT7 cell line. This system enabled us to
explore the mechanisms by which the EPOR mutations affect
the cells, and showed that all three mutations could induce
ligand-independent growth of cells expressing them and
increase the sensitivity of cells expressing them to EGF,
which replaces EPO in this system, and induce enhanced
proliferation rates. It also enabled us to show, for the first
time, that even missense mutations in the cytosolic portion
of EPOR can confer enhanced proliferation.
(A)
(B)
Fig 5. Degradation of EGFR-EPOR chimeras. UT7 cells stably expressing each of the three EGFR-EPOR chimeras were subjected to 035 mmol/l
cycloheximide (CHX) for 5 h. Cell lysates were prepared at the indicated time intervals, and were further subjected to Western blot analysis with
anti-HA antibodies. (A) Representative Western blots of protein extracts from cells treated with CHX. (B) Mean values of the quantifications of
the Western blots. Degradation of each EGFR-EPOR chimera was calculated with respect to the corresponding time 0, which was considered
100%. N ≥ 3. **P < 005 compared to WT levels at the same time. Boxes mark significantly different values. Standard errors of the means are
not included due to visual constraints. WT, wildtype; EGFR, epidermal growth factor receptor; EPOR, erythropoietin receptor.
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A unique property of the EPOR is its high intracellular
retention and low surface expression levels (Ravid et al,
2007). In that respect, although the expression levels of all
EGFR-EPOR chimeras were similar, the truncated chimeric
receptors (C1370A and Del1377-1411) had an increased level
of the glycan-mature form compared to both the WT chi-
mera and the chimera harbouring the G1445A missense
mutation. This may indicate that the shorter forms of the
receptor fold better, and emphasize the role of the cytosolic
region of EPOR in proper – or improper – folding of the
protein. This phenomenon can also indicate different interac-
tions of the WT and mutated EPOR cytosolic domains with
the cytosolic transport proteins. In the case of the C1370A
chimeric receptor, the higher levels of the glycan mature
form were in correlation with higher cell surface levels
in both high and low EGF concentrations, compared to WT
chimeric receptors. These findings may indicate that in the
case of the C1370A mutation, the enlarged pool of glycan
mature receptors enables more mature receptors to be
integrated in the membrane at steady state and following
stress, due to low levels of growth factor.
The differences in glycan maturation, however, cannot
solely explain the differences observed in the cell surface levels
of the WT and mutated chimeric receptors. Notably, higher
surface levels of the chimeras may also indicate less endocyto-
sis. In that respect, previous studies show that mutated
EPORs which lack Tyr430, 432 and 480 do not internalize
upon stimulation with EPO (Sulahian et al, 2009). The sur-
face levels of the WT chimeric receptor declined when the
cells were cultured in 001 ng/ml EGF, as opposed to
increased levels at the low EGF concentration observed in the
C1370A, Del1377-1411 and G1445A EGFR-EPORs. In addi-
tion, the MTT proliferation assay revealed that cells express-
ing WT chimera did not proliferate at 001 ng/ml EGF, while
cells expressing all other three mutated receptors displayed
proliferation under these conditions. Given that the increase
in surface levels of the mutated chimeras at low EGF concen-
tration is in correlation with increased EGF sensitivity of cells
(A)
(B)
(C)
(D)
Fig 6. STAT5 and ERK signalling cascades trig-
gered by EGFR-EPORs. Cells expressing the
WT or mutated chimeras were EGF-starved for
24 h and subsequently activated with 100 ng/
ml EGF for the indicated time periods. Cell
lysates were subsequently subjected to Western
blot analysis. (A) Representative Western blots
showing pSTAT5 and STAT5 levels. (B) Quan-
tification of pSTAT levels measured in the
Western blots. (C) Representative Western
blots showing pERK1/2 and ERK1/2 levels. (D)
Quantification of pERK1/2 levels measured in
the Western blots. Relative pSTAT or pERK
levels of each EGFR-EPOR chimera was calcu-
lated with respect to the corresponding STAT
or ERK levels respectively, at time 10 min,
which was considered 100%. Graphs indicate
mean values, N ≥ 3. **P < 005 compared to
WT levels at the same time points. Standard
errors of the means are not included due to
visual constrains. WT, wildtype; EGF, epider-
mal growth factor; EGFR, epidermal growth
factor receptor; EPOR, erythropoietin receptor;
t, total; p, phosphorylated; STAT5 Signal
Transducer and Activator of Transcription 5;
ERK, extracellular-signal-regulated kinase.
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expressing these mutated chimeras, the results may indicate
more effective activation or initiation of signalling cascades of
these mutated receptors.
Extended EPOR signalling often leads to increased cell
proliferation. Most of the information obtained regarding the
role of each phosphorylated tyrosine residue of EPOR was
collected from experiments performed with murine EPOR.
Despite the differences in the human and murine EPORs,
analogous tyrosine residues are found on both receptors.
Based on information retrieved from studies on murine
EPOR, the following is known: (i) STAT5 binds to phos-
phorylated Tyr344 (pTyr344) and pTyr402 (Wojchowski
et al, 1999) of the human EPOR, (ii) STAT1 and STAT3
associate with pTyr432 (Kirito et al, 2002), (iii) AP-1 tran-
scription factor binds to pTyr344 and pTyr465 (Bergelson
et al, 1998), (iv) shc-Grb2, which activate the MAPK cascade,
bind mostly to pTyr465 though they can also be associated
with other tyrosine residues (Barber et al, 1997) and (v) the
p85 subunit of the PI-3Kinase binds to pTyr480 (Wojchowski
et al, 1999). Simultaneously, negative regulatory mechanisms
inhibit EPO-induced signalling, causing it to return its level
to basal levels after 30–60 min of EPO stimulation (Kralovics
& Prchal, 2001; Hortner et al, 2002). Among these negative
regulatory molecules are SHP-1, which binds to pTyr430
and pTyr432, dephosphorylates JAK2 and shuts down the
signalling cascades triggered by EPOR (Maran & Prchal,
2004; Minoo et al, 2004), and SOCS3, which acts as E3
ubiquitin ligase (Hortner et al, 2002) and down-regulates
EPOR-induced signal transduction.
Here we examined two signalling cascades, STAT5 and
MAPK/ERK, which were both activated by all the chimeric
receptors. One of the chimeric receptors, C1370A, lacks all
tyrosine residues apart from the first one, Tyr344. Given
that phosphorylation of ERK was observed in cells express-
ing the EGFR-EPOR bearing this mutation, following acti-
vation by EGF, we have concluded that, apart from its
known role in STAT5 binding, pTyr344 it is also able to
facilitate the MAPK/ERK signalling cascade. C1370A was
found to be constitutively active, because levels of pSTAT5
were detected even after 24 h of serum and EGF starvation
(time 0, Fig 6A–B). This finding correlates with our obser-
vation that, unlike cells expressing the WT chimera, cells
expressing EGFR-EPOR C1370A display ligand-independent
growth (data not shown). This may be explained by the
shorter form of the receptor and the lack of most of the
tyrosine residues that are involved in the negative regula-
tion of the receptor (Sokol et al, 1995; Kralovics et al,
1997; Perrotta et al, 2010), and is, to date, the first descrip-
tion of a mutation in the cytosolic region of EPOR which
confers constitutive activation of STAT5 signalling. The
MAPK/ERK cascade appears to be similar in the WT and
the mutated EGFR-EPOR chimeras despite a slower attenu-
ation of the signal conferred by the G1445A chimera. This
prolonged activation of the MAPK/ERK cascade may be
one of the underlying mechanisms responsible for the
elevated proliferation rates displayed by cells expressing chi-
meras bearing that missense mutation. In addition, a differ-
ent activation pattern has been observed in G1445A for
both STAT5 and MAPK/ERK signalling cascades. Their acti-
vation is delayed and lower levels of phosphorylated STAT5
or ERK are observed after 5 min of EGF stimulation, com-
pared to their levels in cells expressing the WT chimera at
the same time.
The proteasome complex prevents the renewal of surface
EPOR by inhibiting the insertion of newly-synthesized EPOR
into the cell membrane (Verdier et al, 2000). The main
signal for proteasomal degradation is lysine-related ubiquiti-
nation. The cytosolic region of the murine EPOR contains 5
lysine residues (Yosha et al, 2011). The human EPOR cyto-
solic domain contains 6 lysines at positions 255, 257, 277,
349, 389 and 429. Two of the EPOR mutations, C1370A and
Del1377-1411, lack only Lys 429, but C1370A lacks also
Lys389. This latter EPOR mutant displays a slower degrada-
tion rate, implying possible involvement of the proteasome-
related degradation pathway.
In summary, the EGFR-EPOR chimeras enable us to
explore mechanisms underlying PFCP-inducing mutations in
the cytosolic region of EPOR at a better resolution than cur-
rently available. We have found that all the three novel
EPOR mutations increased the sensitivity of UT7 cells to low
growth factor concentration and conferred enhanced prolifer-
ation. Each mutation influenced unique aspects regarding
signalling and metabolism of the corresponding EGFR-EPOR
chimera. Despite the clustered proximity of the mutations,
they all induced the polycythaemic phenotype, yet via differ-
ent mechanisms.
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